Sie suchten nach: ebv (Englisch - Litauisch)

ebv infection
ebv infekcija susijusi

ebv is the virus that causes glandular fever.
Šis virusas sukelia infekcinę mononukleozę.

viral infection cmv reactivation ebv reactivation bacterial infection
virusinė infekcija cmv reaktyvacija ebv reaktyvacija bakterinė infekcija

ebv (epstein-barr virus) lymphoproliferative disease
ebv (epstein-barr viruso) sukelta limfoproliferacinė liga;

ebv serology should be ascertained before starting administration of belatacept.
prieš skiriant belatacepto reikia ištirti ebv serologinę būklę.

during treatment, careful monitoring with ebv-pcr is recommended.
gydymo metu taip pat reikia kontroliuoti atliekant ebv pgr.

patients treated with tacrolimus have been reported to develop ebv-associated lymphoproliferative disorders.
takrolimuzu gydomiems pacientams pasireisk su ebv susijusios limfinio audinio proliferacins ligos.

positive ebv-pcr may persist for months and is per se not indicative of lymphoproliferative disease or lymphoma.
ebv-pcr gali islikti teigiamas kelis mnesius, tai savaime nerodo limfinio audinio proliferacins ligos ar limfomos.

a combination of immunosuppressives such as antilymphocytic antibodies given concomitantly increases the risk of ebv-associated lymphoproliferative disorders.
imunosupresant derini vartojimas, pvz., kartu vartojami antilimfocitiniai antiknai, didina su ebv susijusi limfinio audinio proliferacini lig rizik.

benign as well as malignant neoplasms including ebv-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.
aprasyti su takrolimuzu susij tiek gerybiniai, tiek piktybiniai navikai, skaitant su ebv susijusias limfinio audinio proliferacins ligas ir odos piktybinius darinius.

therefore, in this patient group, ebv-vca serology should be ascertained before starting treatment with advagraf.
todl, siai pacient grupei, pries pradedant gydym advagraf, reikia nustatyti ebv-vka serologij.

transplant recipients who are ebv seronegative or serostatus unknown should not receive belatacept (see section 4.3).
transplantato recipientams, kurie yra serologiškai neigiami epstein-barr viruso (ebv) požiūriu, arba kurių serologinė būklė nežinoma, belatacepto vartoti negalima (žr. 4.3 skyrių).

ebv-viral capsid antigen (vca)-negative patients have been reported to have an increased risk of developing lymphoproliferative disorders.
pacientams, kuri organizme nra ebv ­ viruso kapsids antigeno (vka) , yra didesn limfinio audinio proliferacini lig pasireiskimo rizika.